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Background: Since RNA expression differences have been reported in autism spectrum disorder (ASD) for blood
and brain, and differential alternative splicing (DAS) has been reported in ASD brains, we determined if there was
DAS in blood mRNA of ASD subjects compared to typically developing (TD) controls, as well as in ASD subgroups
related to cerebral volume.
Methods: RNA from blood was processed on whole genome exon arrays for 2-4–year-old ASD and TD boys. An
ANCOVA with age and batch as covariates was used to predict DAS for ALL ASD (n=30), ASD with normal total
cerebral volumes (NTCV), and ASD with large total cerebral volumes (LTCV) compared to TD controls (n=20).
Results: A total of 53 genes were predicted to have DAS for ALL ASD versus TD, 169 genes for ASD_NTCV versus
TD, 1 gene for ASD_LTCV versus TD, and 27 genes for ASD_LTCV versus ASD_NTCV. These differences were
significant at P <0.05 after false discovery rate corrections for multiple comparisons (FDR <5% false positives). A
number of the genes predicted to have DAS in ASD are known to regulate DAS (SFPQ, SRPK1, SRSF11, SRSF2IP, FUS,
LSM14A). In addition, a number of genes with predicted DAS are involved in pathways implicated in previous ASD
studies, such as ROS monocyte/macrophage, Natural Killer Cell, mTOR, and NGF signaling. The only pathways
significant after multiple comparison corrections (FDR <0.05) were the Nrf2-mediated reactive oxygen species (ROS)
oxidative response (superoxide dismutase 2, catalase, peroxiredoxin 1, PIK3C3, DNAJC17, microsomal glutathione
S-transferase 3) and superoxide radical degradation (SOD2, CAT).
Conclusions: These data support differences in alternative splicing of mRNA in blood of ASD subjects compared to
TD controls that differ related to head size. The findings are preliminary, need to be replicated in independent
cohorts, and predicted alternative splicing differences need to be confirmed using direct analytical methods.
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Autism spectrum disorder (ASD) is a spectrum of
neurodevelopmental disorders that are clinically defined
by communication and social impairments combined
with stereotypic and repetitive behaviors [1]. Though
over 20% of those diagnosed with ASD have a number
of identifiable genetic causes [2], the genetic bases for* Correspondence: boryana.stamova@ucdmc.ucdavis.edu
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reproduction in any medium, provided the orthe remaining cases remain unclear. It is not known
how many other genetic causes of ASD may be identi-
fied, or if there is a group of susceptibility genes that
interact with environmental factors (for example, toxins,
infection, immune) and cause the majority of cases of
ASD [2-4].
A role for both genetics and environment in ASD has
come from many studies, including a recent study of
ASD brain. Regional patterns of gene expression that
distinguish frontal and temporal cortex were attenuated
in ASD brain compared to controls [5]. Moreover, there
were two modules of co-expressed genes associated withal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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autism susceptibility genes (genetic module); and a
module enriched for immune and glial genes that were
not enriched for autism GWAS-associated genes (envir-
onmental immune module) [5]. Significantly for the
present study, some genes showed evidence of altered
differential alternative splicing (DAS) of specific FOX1
regulated mRNAs [5].
These data led us to consider in this study whether
there might be altered DAS of mRNA in ASD blood.
Blood is useful to study in ASD for several reasons: (1)
various factors - including genetics, toxicants, infections,
immune and autoimmune factors implicated in ASD
[6-11] - affect alternative splicing in leukocytes in blood
[12-19]; (2) the monocyte transcriptome in blood is very
similar to the microglia (brain macrophage) transcrip-
tome [20,21], and microglia are activated in ASD brain
[22]; (3) immune and autoimmune dysfunction that
would be associated with alterations of gene expression
and alternative splicing in blood has been reported in
subgroups of ASD individuals [23-26]; (4) there is cross-
talk between the immune system and the CNS [27,28];
(5) studies of blood allow us to investigate subjects at an
early age when ASD becomes clinically evident.
In recruiting subjects for this study, we included ASD
boys that were ultimately found to have altered trajector-
ies of brain development. Abnormal brain enlargement
has been consistently observed in MRI studies of
preschool-aged ASD children compared to age-matched
controls [29-31]. This is one of the most consistent find-
ings in the neuropathology of a subset of ASD in boys,
however there is considerable variability in total cerebral
volume (TCV) phenotypes. Macrocephaly has been
reported in 15% to 20% of young children with ASD
[29,31-34] , though there is an ongoing debate for its
relevance in ASD [35,36]. In the larger population of
children recruited for this study, approximately 15% had
abnormally enlarged TCV [30]. In addition, PTEN
(phosphatase and tensin homolog deleted on chromo-
some 10) mutations are found in a subset of ASD chil-
dren with macrocephaly [37-39]. It has been suggested
that PTEN may regulate cell size through effects on pro-
tein translation, particularly interesting in the view of its
connection to PI3K/AKT/mTOR signaling pathways im-
plicated in single gene causes of ASD [40]. Finally, differ-
ences of differential alternative splicing have been
associated with abnormal brain volumes in various ani-
mal models and in humans [41-44].
We therefore postulated that specific differences in al-
ternative splicing/exon usage in immune blood cells may
be present in ASD boys, and this might differ in ASD
boys with large total cerebral volumes (ASD_LTCV)
versus ASD boys with normal total cerebral volumes
(ASD_NTCV). Thus, we compared ASD and ASDsubgroups related to total cerebral volume to typically
developing (TD) controls. Our findings demonstrate
DAS in ASD versus TD boys, and that there are differ-
ences of DAS in ASD boys with large brains compared
to those with normal total cerebral volumes. Finally,
there are some genes that demonstrate DAS in blood in
this study that have previously been reported to have
DAS in brain [5]. However, most of the DAS blood
genes are different from DAS brain genes which would
be consistent with differential alternative splicing gener-
ally being tissue specific [45-48].
Methods
Subjects
This study was approved by the University of California
at Davis Institutional Review Board (IRB). Written in-
formed consent was obtained from the parent or guard-
ian of each participant and data were analyzed without
personal information identifiers.
Fifty boys (n=20 TD and n=30 ASD), aged 2-4 years,
participated in this study. Participants were enrolled in
the UC Davis MIND Institute’s Autism Phenome Project
(APP) (http://www.ucdmc.ucdavis.edu/mindinstitute/re-
search/app/). The diagnostic criteria for ASD and TD
and inclusion and exclusion criteria were previously de-
scribed [30]. Briefly, subjects were recruited through the
MIND Institute at the University of California, Davis.
ASD diagnosis was determined based on administration
of the Autism Diagnostic Observation Schedule-Generic
(ADOS-G) [49], and the Autism Diagnostic Interview-
Revised (ADI-R) [50] by appropriately trained members
of the research team and clinical consensus of two inde-
pendent psychologists. Autism severity was determined
by using the ADOS severity score, based on the algo-
rithm scores on the various modules [51]. Developmen-
tal abilities of cases and controls were determined using
the Mullen Scales of Early Development [52]. In
addition, several inclusion and exclusion criteria were
used for the TD group. TD inclusion was based on hav-
ing Standard Score of 70-130 on the Learning Compos-
ite of the Mullens Scale of Early Learning, and a score
<11 on the Social Communication Questionnaire used
to screen for autism traits [53]. Exclusion criteria for the
TD group included a diagnosis of intellectual disability,
pervasive developmental disorder, specific language im-
pairment, or any known developmental, neurological, or
behavioral problems [30].
In addition, if the ASD or TD children had a fever or
had been ill within the 2 weeks before the blood draw,
blood draws were rescheduled for a later time. This
method was used to exclude children with acute infec-
tions in a previous CHARGE study [54]. Clinical infor-
mation collected for the kids from this study showed six
were on different prescription and non-prescription
Stamova et al. Molecular Autism 2013, 4:30 Page 3 of 16
http://www.molecularautism.com/content/4/1/30medications (6 ASD/0 TD), and 25 (17 ASD/8 TD) were
on supplements (mostly vitamins). Since no two ASD or
TD individuals were on the same medication or supple-
ment, and times varied since the last doses, these were
not included as covariates in the analyses and there were
too few medication- and supplement-free subjects to
analyze separately.MRI of brain
Because total cerebral volume (TCV) is extremely vari-
able in ASD [30], ASD participants were selected to have
a range of TCV. As part of the APP, all participants
underwent MRI scanning at the UC Davis Imaging Re-
search Center, as previously described [30]. In short, all
scans were acquired during natural, nocturnal sleep.
Total cerebral volume (TCV) data were measured from
a three-dimensional T1-weighted MPRAGE scan (TR,
2,170 ms; TE, 4.86 ms; matrix, 256 × 256; slices acquired
in sagittal direction, 192; isotropic voxels, 1 mm). Distor-
tion correction using a calibration phantom was carried
out and images were corrected for field in homogeneity.
TCV was measured using a template-based automated
method, and excluded brainstem and cerebellum [30].
ASD subjects were divided into two subgroups based on
MRI measures of TCV, with the ones with NTCV (n=20
ASD subjects) having TCV within 1.5 standard deviations
of the TD centroid [30], while the ones with LTCV (n=10)
had TCV >1.5 standard deviations of the TD controls.RNA and array processing
Whole venous blood was collected into PAXgene tubes
(PreAnalytiX, Germany), which immediately lyse all cells
in whole blood and stabilize the RNA without measurable
degradation or ex vivo transcriptional changes. RNA was
isolated and processed as previously described [55] using
the WT-Ovation™ Pico RNA Amplification System
(NuGEN, San Carlos, CA, USA) with the Exon Module
and fragmented and labeled using the FL Ovation™ cDNA
Biotin Module V2 (NuGEN, San Carlos, CA, USA). Ex-
pression was measured by hybridization on Affymetrix
Human Exon 1.0 ST microarrays according to protocol
(Affymetrix, Santa Clara, CA, USA).
Probe summarization and probe set normalization were
performed using robust multi-chip average (RMA) in
Partek Genomics Suite 6.5 software (Partek Inc., St. Louis,
MO, USA). RMA includes background correction, Quan-
tile Normalization, log2-transformation, and Median Pol-
ish probe set summarization. Only the core meta-probe
sets (about 228,000 probe sets) were analyzed since these
are the best annotated. Exons with low signal in all sam-
ples (maximum signal across all samples of the log2-
transformed probe set value <3), were considered not
expressed and were excluded from further analysis.Analysis of predicted DAS
Since the exon array used does not contain probe sets
covering exon-exon junctions, deducing DAS is indirect
given that the unit measured is exon expression which
provides a measure of exon usage. Thus we will often
use the term predicted ‘differential alternative splicing/
differential exon usage (DAS/DEU)’ to emphasize the
fact that differential exon expression is used to predict
DAS in these studies.
An alternative splicing ANCOVA was performed on the
probe sets passing the filtering criteria using Partek soft-
ware. The Splicing ANCOVA Model [56,57] used was:
Yijklm ¼ μþ Groupi þ Ageþ Batchj þMarkerIDk
þ SampleID Group  Batchð Þijl
þ Group MarkerIDik þ Age MarkerIDk
þ Batch MarkerIDjk þ εijklm
Where:
 Yijklm represents the mth observation on the ith
Group, jth Batch, kth MarkerID, lth SampleID.
 μ is the common effect for the whole experiment.
 εijklm represents the random error present in the mth
observation on the ith Group, jth Batch, kth
MarkerID, lth SampleID. The errors εijklm are
assumed to be normally and independently
distributed with mean 0 and standard deviation
δ for all measurements.
SampleID(Group * Batch)ijl is a sample-to-sample ef-
fect. SampleID is a random effect. Batch is a random
effect.
MarkerIDk is exon-to-exon effect (alt-splicing inde-
pendent to Group). This term also accounts for the fact
that not all exons of a gene hybridize to the correspond-
ing probe sets (MarkerID) with the same efficiency.
Group * MarkerIDik, Age * MarkerIDk, Batch *
MarkerIDjk represent whether an exon expresses differ-
ently in different level of the specified alternative splice
factor(s). The term Group * MarkerIDik was used to
identify group-specific DAS.
Thus, an alternative splicing ANCOVA was performed
on the 17,100 genes passing the filtering criteria (max-
imum signal across all samples of the log2-transformed
probe set value <3, as described in the above section). The
splicing ANCOVA model included covariates for both
technical (batch, random effect) and biological (age, con-
tinuous variable) variation to account for their effect on
DAS/DEU. In addition, since not all exons in a gene
express/hybridize to the probe sets at the same level,
MarkerID was added to the model to account for exon-to
-exon differences. MarkerID is an exon-to-exon effect (alt-
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the model, which accounted for the sample-to-sample
effect. An interaction term of MarkerID with Group
(ASD, TD) to detect alternative splicing was used to esti-
mate an exon has a different expression in different levels
of the factor (ASD, TD), which was used to identify genes
with predicted DAS/DEU in the different groups. The
splicing prediction algorithm within Partek software
was used.
Separate differential alternative splicing ANCOVAs
were performed for the following comparisons: All ASD
versus TD; ASD_LTCV versus TD; ASD_NTCV versus
TD; and ASD_NTCV versus ASD_ LTCV. To correct for
the multiple comparisons being performed, a Benjamini-
Hochberg false discovery rate of 5% was adopted, mean-
ing that the P values were adjusted so that no more than
5% of the reported genes would be expected to be false
positives [58].
Hierarchical clustering and principal component analyses
Hierarchical clustering using Euclidean distance and
average linkage, and the principal components analysis
(PCA) were performed in Partek Genomics Suite. For
each analysis, the exon-level expression data corrected
for age and batch were used. Genome-wide PCA using
all probe sets on the array and all samples was
performed to examine array quality and visualize vari-
ability at the whole-genome level (Additional file 1:
Figure S1).
Functional pathways associated with DAS in ASD
Ingenuity pathway analysis (IPA) was used to identify
the pathways from the IPA library of canonical pathways
that were most significant to each dataset. The signifi-
cance of the association between the dataset with pre-
dicted DAS/DEU and canonical pathways was assessed
by calculating the ratio of the number of genes from the
dataset that map to the pathway divided by the total
number of molecules that exist in the canonical path-
way. A Fisher’s exact test was then used to calculate a
P value determining the probability that each biological
function and/or pathway assigned to that dataset is due
to chance alone. A FDR (5% false positives) corrected
P <0.05 was considered to be statistically significant for
over-representation of the molecules in a given pathway.
Thus, over-represented canonical pathways are those
with more molecules than expected by chance.
The above analyses used standard criteria for identify-
ing ASD pathways associated with DAS/DEU. However,
as outlined in the results below, only two pathways were
identified using the DAS/DEU genes that passed FDR
correction. We therefore performed a sub-analysis in
order to obtain a broader picture of possible regulated
pathways. Thus, a splicing ANCOVA was performed forAll ASD versus TD, except that all genes showing a
P <0.05 for DAS were identified. An exon-level expres-
sion ANCOVA was then performed on these genes for
ALL ASD versus TD, including age and batch as covari-
ates. Exons with expression significantly different be-
tween All ASD and TD with P <0.005 and |Fold-
Change| >1.2 were considered significant in this analysis.
This approach would help correct for multiple compari-
sons and should identify the most reliable DAS genes
because they were predicted to be differentially alterna-
tively spliced, and to have significant differences of
exon-level expression for All ASD versus TD (overlap
P <0.0002). An Ingenuity pathway analysis was then
performed on this list of genes for ALL ASD versus TD
with P <0.05 considered significant.Results
Participants’ characteristics
Demographic and clinical characteristics of the subjects
are presented in Table 1. There were 20 ASD_NTCV
subjects (3.0 ± 0.5 years), 10 ASD_LTCV subjects (3.1 ±
0.2 years), and 20 TD subjects (3.0 ± 0.3 years). Seven
out of the 10 ASD_LTCV subjects were classified as
megalencephalic, defined as having TCV >2 standard de-
viations above the TD mean. There were no significant
group differences in age or race. As expected, develop-
mental quotient (DQ), verbal quotient (VQ), and non-
verbal quotient (NVQ) were significantly lower in the
ASD than the TD groups (P <1E-09). Total cerebral vol-
ume (TCV) was not significantly different between the
ASD_NTCV and TD groups (P=0.87). TCV was signifi-
cantly enlarged in the ASD_LTCV compared to
ASD_NTCV (P=2.42E-10) and TD (P=1.42E-09), which
was the result of our pre-selection. There were no sig-
nificant differences in the ADOS severity scores between
the ASD_NTCV and ASD_LTCV groups (P=0.17).DAS/DEU in ASD groups compared to TD
There were 53 genes with predicted DAS/DEU for the
comparisons of ALL ASD versus TD (Table 2, Additional
file 2: Table S1) (FDR corrected P <0.05). The cluster
analysis (Figure 1A) and Principal Components Analysis
(Figure 1B) using these genes demonstrated good separ-
ation of the subjects in each group with a few exceptions
(Figure 1).
There were 169 genes with predicted DAS/DEU for the
comparisons of ASD_NTCV versus TD (FDR corrected
P <0.05) (Additional file 2: Table S2). The cluster analysis
(Figure 2A) and principal components analysis (Figure 2B)
using these genes demonstrated excellent separation of
the subjects in each group with no exceptions (Figure 2).
There was only one gene with predicted DAS/DEU for
the comparison of ASD_LTCV versus TD (FDR corrected
Table 1 Demographic and clinical characteristics of









Subjects 20 30 20 10
Age (years)
Mean ± SD 3.0 ± 0.3 2.9 ± 0.4 3.0 ± 0.5 3.1 ± 0.2
Gender
Male, n (%) 20 (100%) 30 (100%) 20 (100%) 10 (100%)
Race, n (%)
White 14 (70%) 15 (50%) 11(55%) 4 (40%)
Black 0 (0%) 3 (10%) 2 (10%) 1 (10%)
Asian 0 (0%) 1 (3%) 1 (5%) 0 (0%)
Other 0 (0%) 1 (3%) 1 (5%) 0 (0%)
Mixed 3 (15%) 2 (7%) 1(5%) 1 (10%)
Unknown 3 (15%) 8 (27%) 4 (20%) 4 (40%)
TCV (cm3)









Mean ± SD NA 8.0 ± 1.7 8.3 ± 1.7 7.4 ± 1.6
Developmental
quotient (DQ)
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ing frame 6) which is also called membralin (MBRL).
There were 27 genes with predicted DAS/DEU for the
comparisons of ASD_LTCV versus ASD_NTCV (FDR
corrected P <0.05) (Table 3, Additional file 2: Table S3).
The cluster analysis (Figure 3A) and principal compo-
nents analysis (Figure 3B) using these 27 genes demon-
strated excellent separation of the subjects in each group
(Figure 3).
Pathway analyses
Pathway analysis on each of the above lists of genes
showed that only two pathways were significantly differ-
ent at P <0.05 after FDR correction for multiple compar-
isons (FDR <5% false positives). These two pathwayswere for the 53 genes for ALL ASD versus TD compari-
son and included: (1) the Nrf2-mediated oxidative stress
response (SOD2, CAT, PRDX1, PIK3C3, DNAJC17, and
MGST3); and (2) the superoxide radical degradation
(SOD2, CAT). This pathway analysis was supplemented
by a network analysis which considered all of the up- and
downregulated FDR passing genes and included direct as
well as indirect interactions. The number one network
for All ASD versus TD was: Free Radical Scavenging,
Cell Death and Survival, Small Molecule Biochemistry
(Additional file 1: Figure S2), which had PI3K as one of
the central hubs. Notably, the second highest scoring
network in ASD_LTCV versus ASD_NTCV included
genes involved in RNA post-transcriptional modification
with Ubiqiutin C as a central hub of direct interactions
(Additional file 1: Figure S3).
As described in the Methods section, we performed a
sub-analysis to identify additional pathways associated
with ASD versus TD. There were 477 genes predicted to
have DAS between ALL ASD versus TD (P <0.05) and
that had significant differences in exon expression be-
tween ASD and TD (P <0.005) and a fold change of at
least 1.2 or more (Additional file 2: Table S4). IPA ana-
lysis of these 477 genes revealed 21 pathways that were
significantly different for ALL ASD versus TD (P <0.05)
(Additional file 2: Table S5).
We then determined which of the 21 pathways were
dysregulated in each ASD individual. To do this unique
analysis, PCA mapping was performed based on exon-
level expression of the genes predicted to have DAS/
DEU in each pathway found to be over-represented with
genes with DAS/DEU. For example, the PCA plot of the
mTOR signaling pathway (Figure 4, upper right inset)
was based on the expression level of eight exons in
mTOR genes predicted to have DAS/DEU (Additional
file 2: Table S5). Based on the PCA position of each
ASD subject, the mTOR signaling pathway was scored
as TD-like (if within 2 standard deviations of the TD
centroid), or non-TD-like (if outside the 2 standard devi-
ations of the TD centroid) (Figure 4, upper right inset).
The same procedure was then performed for each of the
21 significantly over-represented canonical pathways,
with each individual being assigned either as being ‘TD-
like ASD’ (black rectangles) or ‘non-TD-like ASD’ (gray
rectangles) for each pathway (Figure 4). Hierarchical
clustering of the ASD subjects and the 21 canonical
pathways (Figure 4) showed that different combinations
of pathways were affected (non-TD-like ASD, gray rect-
angles) in different ASD subjects (Figure 4). No pathway
was affected in every subject. Five ASD subjects had all
21 pathways affected (Figure 4, right side of x-axis clus-
ter), but there were some ASD subjects with only several
pathways affected (Figure 4, left side of x-axis cluster).
The pathways affected in the majority of the ASD
Table 2 Genes (n=53) with predicted DAS/DEU in All ASD
vs. TD groups (FDR P <0.05)
Gene
symbol
Gene title FDR P
(DAS)
CDK13 Cyclin-dependent kinase 13 5.50E-05
USP48 Ubiquitin specific peptidase 48 1.11E-03
SFPQ Splicing factor proline/glutamine-rich 1.11E-03
FXR1 Fragile X mental retardation,
autosomal homolog 1
1.11E-03
C19orf6 Chromosome 19 open reading frame 6 1.85E-03
CAT Catalase 1.85E-03
ZNF330 Zinc finger protein 330 1.85E-03
C19orf2 Chromosome 19 open reading frame 2 1.85E-03
TARS2 Threonyl-tRNA synthetase 2,
mitochondrial (putative)
3.66E-03
LRPPRC Leucine-rich PPR-motif containing 3.86E-03
PIK3C3 Phosphoinositide-3-kinase, class 3 4.65E-03
CLTB Clathrin, light chain B 5.13E-03
SOD2 Superoxide dismutase 2, mitochondrial 6.11E-03
OS9 Osteosarcoma amplified 9, endoplasmic
reticulum lectin
6.11E-03
ACPT Acid phosphatase, testicular 6.71E-03
PPP2R2A Protein phosphatase 2, regulatory
subunit B, alpha
1.05E-02
C14orf159 Chromosome 14 open reading frame 159 1.05E-02




EAPP E2F-associated phosphoprotein 1.22E-02
PIP4K2A Phosphatidylinositol-5-phosphate
4-kinase, type II, alpha
1.24E-02
TADA3 Transcriptional adaptor 3 1.65E-02
PRSS36 Protease, serine, 36 2.17E-02
HELQ Helicase, POLQ-like 2.17E-02
EMD Emerin 2.47E-02
C1orf175 Chromosome 1 open reading frame 175 2.77E-02
AEBP2 AE binding protein 2 2.86E-02
R3HDM1 R3H domain containing 1 2.96E-02
SRPK1 Serine/arginine-rich splicing factor kinase 1 3.29E-02
LEF1 Lymphoid enhancer-binding factor 1 3.29E-02
MPHOSPH10 M-phase phosphoprotein 10
(U3 small nucleolar ribonucleoprote
3.29E-02
PRDX1 Peroxiredoxin 1 3.29E-02
MPP1 Membrane protein, palmitoylated 1, 55kDa 3.29E-02
CNOT2 CCR4-NOT transcription complex, subunit 2 3.53E-02
GOLGA7 Golgin A7 3.53E-02
WDR67 WD repeat domain 67 3.61E-02
AAMP Angio-associated, migratory cell protein 4.10E-02
KLHL9 Kelch-like 9 (Drosophila) 4.24E-02
Table 2 Genes (n=53) with predicted DAS/DEU in All ASD
vs. TD groups (FDR P <0.05) (Continued)
CC2D1A Coiled-coil and C2 domain containing 1A 4.49E-02
STAT4 Signal transducer and activator
of transcription 4
4.49E-02
DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 4.51E-02
MGST3 Microsomal glutathione S-transferase 3 4.51E-02
TEPP Testis, prostate, and placenta expressed 4.51E-02
UTRN Utrophin 4.51E-02
PUM2 Pumilio homolog 2 (Drosophila) 4.51E-02
CHID1 Chitinase domain containing 1 4.51E-02
GFER Growth factor, augmenter of liver
regeneration
4.51E-02
RPGR Retinitis pigmentosa GTPase regulator 4.51E-02
SUCLA2 Succinate-CoA ligase, ADP-forming,
beta subunit
4.72E-02
ZNF512B Zinc finger protein 512B 4.72E-02
MORN2 MORN repeat containing 2 4.72E-02
DNAJC17 DnaJ (Hsp40) homolog, subfamily
C, member 17
4.88E-02
FGD3 FYVE, RhoGEF and PH domain containing 3 4.88E-02
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naling, FCγ Receptor-mediated phagocytosis in macro-
phages and monocytes, and HMGB1 signaling (Figure 4,
lower portion of cluster). The mTOR pathway was al-
tered in 18 out of 30 ASD subjects (Figure 4). We
performed this clustering analysis not so much to show
clustering of pathways, since a number of these path-
ways contained common genes with DAS, but to identify
clustering of subjects with particular sets of pathways
being affected.Discussion
This study shows that differential alternative splicing
may occur in selected genes in blood of 2-4-year-old
boys with ASD compared to TD controls. There was an
over-representation of DAS genes for pathways associ-
ated with the Nrf2-mediated oxidative stress response
and superoxide radical degradation. In addition, there
were genes with DAS from the Natural Killer cell,
monocyte, NGF, and mTOR signaling pathways,
which have been implicated in previous ASD studies
[38,40,59-62]. An interesting result was that DAS in
blood of ASD boys appeared to be more associated with
normal cerebral volumes than with large cerebral vol-
umes. Though the data are limited by small sample size
and dependence of DAS predictions from exon arrays,
they provide support for DAS occurring in blood as well
as that already reported in brain [5], and will provide
candidate genes for subsequent confirmatory studies.
Figure 1 All ASD vs. TD. Unsupervised hierarchical clustering (A) and PCA (B) of the 53 exons predicted to display DAS/DEU with FDR P <0.05
in All ASD vs. TD analysis. The heatmap in 1A represents adjusted exon expression level (high=red, low=green) of the exons predicted to have
DAS/DEU. TD subjects denoted in blue; ASD subjects - in black. The PCA plot in 1B shows separation of the ASD (red spheres) from the TD
(blue spheres) subjects. The ellipsoids are drawn at 2 standard deviations around the group centroids.
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DAS was predicted for specific genes in the superoxide rad-
ical degradation and Nrf-2 mediated oxidative stress path-
ways which were significant for the ALL ASD versus TD
comparison. SOD2 is a mitochondrial matrix protein that
transforms toxic superoxide, a by-product of the mitochon-
drial electron transport chain, into hydrogen peroxide and
diatomic oxygen. Mice without SOD2 die shortly after birth
[63]. Catalase decomposes toxic hydrogen peroxide produced
by SOD to water and oxygen. Peroxiredoxin 1 (PRDX1) cata-
lyzes peroxide reduction of hydrogen peroxide, organic hy-
droperoxides, and peroxynitrite, and thus decreases oxidative
stress in cells. The MGST3 gene encodes the enzyme
Microsomal glutathione S-transferase 3 which demonstrates
glutathione-dependent peroxidase activity towards lipid hy-
droperoxides. All of these genes are induced by reactive oxy-
gen species (ROS). ROS cause the transcription factor Nrf2
to translocate from cytoplasm to the nucleus where Nrf2
binds anti-oxidant response elements (ARE) in promoters of
Nrf2 target anti-oxidant genes including SOD2, CAT,
PRDX1, and MGST3 to increase RNA expression [64].
There is some evidence of oxidative stress [65-68] and ab-
normal levels of superoxide and catalase in blood of ASD
children [69-71]. There is also increased oxidative stress inASD brain and specific abnormalities related to glutathione
and superoxide [67,72]. Moreover, mitochondrial abnormal-
ities have been identified in blood of ASD subjects [9] that
could contribute to ROS production and alterations of Nrf2
and SOD2 pathways identified here. Mitochondrial abnor-
malities are also found in brain [73]. Though oxidative stress
may not be causal, the results of the current study support
the possibility of DAS in specific oxidative stress genes in
peripheral blood cells is associated with ASD. This associ-
ation probably is not specific since evidence of oxidative
stress is seen in other neurodevelopmental disorders and
also occurs during normal function of the immune system.
Regulators of alternative splicing
A number of the genes predicted to have DAS in
ASD either regulate splicing and/or are transcriptional
regulators. Some of these genes included: SFPQ (splicing
factor proline/glutamine rich), SRPK1 (serine/arginine-
rich splicing factor kinase 1), SRSF11 (serine/arginine-
rich splicing factor 11), SRSF2IP (splicing factor, argin-
ine/serine-rich 2-interacting protein), FUS (fused in
sarcoma), and LSM14A (SCD6 homolog A-yeast).
SFPQ , a DNA and RNA binding protein, is an essential












Figure 2 ASD_NTCV vs. TD. Unsupervised hierarchical clustering (A) and PCA (B) of the 169 exons predicted to display DAS/DEU with FDR
P <0.05 in ASD_NTCV vs. TD analysis. The heatmap in 1A represents adjusted exon expression level (high=red, low=green) of the exons predicted
to have DAS/DEU. TD subjects denoted in blue; ASD_NTCV subjects - in orange. The PCA plot in 1B shows separation of the ASD_NTCV (orange
spheres) from the TD (blue spheres) subjects. The ellipsoids are drawn at 2 standard deviations around the group centroids.
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mRNA in the spliceosome C complex and regulates both
alternative splicing and transcription. SFPQ has been
associated with Alzheimer’s disease [74] and plays a
role in neuronal survival and differentiation during
development [75].
SRPK1 regulates splicing, controlling the intranuclear
distribution of splicing factors in interphase cells, and
regulates splice site selection. Alternative splicing of this
gene results in multiple transcript variants. In brain,
SRPK1 is expressed in cortical and hippocampal pyramidal
neurons, cortical and cerebellar granule cells, and Purkinje
cell neurons, and regulates alternative splicing of glutam-
ate receptor subunit 2 (GluR2) and tau protein [76].
The SRSF11 gene encodes a nuclear protein that con-
tains an arginine/serine-rich region similar to segments
found in other pre-mRNA splicing factors and also plays
a role in pre-mRNA processing and splicing including
the human telomerase protein [77]. The related SRSF2IP
(SCAF11) is another pre-mRNA splicing factor showing
differential alternative splicing in ASD in this study.
The Fus gene encodes a protein component of the het-
erogeneous nuclear ribonucleoprotein (hnRNP) complex
which regulates pre-mRNA splicing and export of fully
processed mRNA to cytoplasm. This protein belongs to
the FET family of RNA-binding proteins which regulate
gene expression and process mRNA/microRNA. Fusproteins are found in brain cytoplasmic inclusions of pa-
tients with fronto-temporal dementia, affect tau splicing,
and Fus mutations have been associated with familial
amyotrophic lateral sclerosis [78]. Fus protein decreases
in cortex during development [79].
LSM14A is homologous to Sm-like (LSm) proteins
which are members of the tri-snRNP (small nuclear ri-
bonucleoprotein) particles that regulate pre-mRNA spli-
cing. Mutations in snRNP proteins have been associated
with neurodevelopmental disorders with ASD features,
including Prader-Willi and Angelman Syndrome [80,81].
Though most of the above genes have not been directly
implicated in ASD, they could affect differential alternative
splicing of ASD susceptibility genes [82]. Moreover, alterna-
tive splicing appears to play a role in some known genetic
causes of ASD. There is aberrant alternative splicing in
single gene mutations associated with ASD (CADPS2,
NLGN3, NLGN4X, NRXN1, and SHANK3). There is
dysregulated splicing in some single gene disorders respon-
sible for some forms of syndromic autism (tuberous scler-
osis and neurofibromatosis); and still other genes associated
with syndromic autisms encode proteins that can modulate
alternative splicing (FMR1, MECP2, and SNRPN-Fragile X
and Retts Syndrome) [82]. In addition, a recent study dem-
onstrated differential expression of mRNA in brain between
ASD and controls, which revealed enrichment of mRNAs
involved in the process of alternative splicing [35].
Table 3 Genes (n=27) with predicted DAS/DEU in
ASD_LTCV vs. ASD_NTCV groups (FDR P <0.05)
Gene
symbol
Gene title FDR P
(DAS)
TMEM204 Transmembrane protein 204 2.26E-05
SRSF2IP Splicing factor, arginine/serine-
rich 2-interacting protein
7.17E-05
PPP1R10 Protein phosphatase 1, regulatory
(inhibitor) subunit 10
4.19E-04
ATXN7L3B Ataxin 7-like 3B 1.52E-03
HPS1 Hermansky-Pudlak syndrome 1 1.90E-03




ZNF493 Zinc finger protein 493 1.51E-02
DHX29 DEAH (Asp-Glu-Ala-His) box polypeptide 29 1.57E-02
HOOK2 Hook homolog 2 (Drosophila) 2.02E-02
IL12RB2 Interleukin 12 receptor, beta 2 2.14E-02
BAT3 HLA-B associated transcript 3 2.53E-02
DVL3 Dishevelled, dsh homolog 3 (Drosophila) 2.53E-02
RAB7A RAB7A, member RAS oncogene family 2.53E-02









DPH2 DPH2 homolog (S. cerevisiae) 3.71E-02
PDP1 Pyruvate dehyrogenase phosphatase
catalytic subunit 1
3.71E-02
TGFB1I1 Transforming growth factor beta
1 induced transcript 1
4.14E-02
UBA6 Ubiquitin-like modifier activating enzyme 6 4.41E-02
SLC38A5 Solute carrier family 38, member 5 4.42E-02
PLCD3 Phospholipase C, delta 3 4.45E-02
COL15A1 Collagen, type XV, alpha 1 4.47E-02
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic
reticulum protein
4.47E-02
BIRC3 Baculoviral IAP repeat-containing 3 4.47E-02
ALOX15 Arachidonate 15-lipoxygenase 4.47E-02
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degradation
The number two network for ASD_NTCV versus TD
was Cellular Assembly, Function and Organization
and RNA Post-Transcriptional Modification which had
Ubiquitin C at its hub (Additional file 1: Figure S2).
There were a number differentially alternatively spliced
genes in our ASD analyses that functioned in regulating
transcription, translation, and protein degradation at
various levels.Transcription
There were many genes with predicted DAS in ASD ver-
sus TD that regulated transcription including POLR2B
(polymerase (RNA) II (DNA directed) polypeptide B,
140kDa). POLR2B encodes the second largest subunit of
RNA polymerase II, the polymerase responsible for syn-
thesizing messenger RNA in eukaryotes. This subunit, in
combination with at least two other polymerase sub-
units, forms a structure within the polymerase that
maintains contact in the active site of the enzyme be-
tween the DNA template and the newly synthesized
RNA, playing a key role in transcription as well as alter-
native splicing. Though not implicated in ASD, in
Alzheimer brain the hyperphosphorylation of RNA poly-
merase II and decreases of RNA levels precede neurofib-
rillary tangle formation [83].
MED12 (mediator complex subunit 12) is a compo-
nent of the Mediator complex, a co-activator involved in
the regulated transcription of nearly all RNA polymerase
II-dependent genes. This subunit may regulate transcrip-
tion of targets of the Wnt signaling pathway and SHH
signaling pathway relevant for neurodevelopment and
intellectual disability syndromes [84-86].
Another DAS gene was TADA3 (Transcriptional
Adaptor 3) which enhances the initiation rate of RNA
polymerase II-mediated gene transcription by interacting
functionally with the general transcription machinery
bound at the basal promoter (see below). Related genes
included MLL3, a histone methyl transferease, which is a
co-activator complex of nuclear receptors, involved in
transcriptional co-activation. The gene is essential for
normal embryogenesis and cell cycle progression [87].
Another related DAS gene is ASH2L (ash2 (absent,
small, or homeotic)-like (Drosophila) is part of the
MLL1/MLL2 histone methyltransferase (HMT) complex.
It is involved in methylation/ demethylation and func-
tions as a transcriptional activator and may play a role in
chromosome demarcation [88].
There were also several transcription factors predicted to
have DAS in ASD including STAT4, CNOT2, and NPAS2
and TCF1 (Transcription Factor 19). NPAS2, a member of
the basic helix-loop-helix (bHLH)-PAS family of transcrip-
tion factors, regulates transcription of proteins involved in
specific types of memory, several proteins (PER1) that are
part of the molecular clock in the mammalian forebrain,
and has been implicated in ASD [89]. STAT4 (signal trans-
ducer and activator of transcription 4) is essential for medi-
ating responses to IL12 in lymphocytes, and regulating the
differentiation of T helper cells. STAT4 regulates perforin
expression in cytotoxic T cells and Natural Killer cells [90],
the latter cells having been shown to have altered cyto-
toxic/perforin functions in ASD [59].
There is evidence for coupling of transcription and spli-












Figure 3 ASD_LTCV vs. ASD_NTCV. Unsupervised hierarchical clustering (A) and PCA (B) of the 27 exons predicted to display DAS/DEU with
FDR P <0.05 in ASD_LTCV vs. ASD_NTCV analysis. The heatmap in 1A represents adjusted exon expression level (high=red, low=green) of the
exons predicted to have DAS/DEU. ASD_LTCV subjects denoted in grey; ASD_NTCV subjects - in orange. The PCA plot in 1B shows separation of
the ASD_NTCV (orange spheres) from the TD (grey spheres) subjects. The ellipsoids are drawn at 2 standard deviations around the
group centroids.
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transcription could result in alterations of DAS in a num-
ber of targets.
Translation
There were also many DAS genes involved in regulating
translation including: PIK3C3 (in mTOR pathway);
PPP1R9B ( protein phosphatase 1, regulatory (inhibitor)
subunit 9B); FXR1 (fragile X mental retardation, autosomal
homolog 1); PPP2R2A (protein phosphatase 2, regulatory
subunit B, alpha-mTOR); ELP2 (elongation protein 2
homolog-yeast); EIF2AK1 (eurkaryotic translation initi-
ation factor 2-alpha kinase 1); MRPL40 (mitochondrial
ribosomal protein L 40); TARS2 (threonyl-tRNA synthe-
tase 2, mitochondrial); YARS (tyrosyl -tRNA synthetase);
and EIF2C3 (eukaryotic translation initiation factor 2C, 3).
These many genes involved in translation relate directly
and indirectly to PI3K/AKT/mTOR pathways, a result
which was also supported by our sub-analysis on the path-
ways affected in each ASD subject discussed below (see
section on Pathways previously implicated in ASD).
Ubiquitination and protein degradation
Several genes with predicted DAS in ASD were related
to ubiquitin pathways, and ubiquitin was a hub in sev-
eral regulated networks (Additional file 1: Figure S2).These genes included USP48 (ubiquitin specific peptid-
ase 48), UBA6 (ubiquitin-like modifier activating enzyme
6), BIRC3 (baculoviral IAP repeat-containing 3), and
DnaJC17 (DNAJ (Hsp40) homolog, subfamily C, mem-
ber 17). BIRC3 Acts as an E3 ubiquitin-protein ligase
regulating NF-kappa-B signaling and regulates both ca-
nonical and non-canonical NF-kappa-B signaling. The
target proteins for its E3 ubiquitin-protein ligase activity
include: RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7,
CASP8, TRAF1, and BCL10. Ubiqutin pathways have
been implicated in autism for some time and are
specifically linked to autism associated with 15q11-q13
chromosome deletions [93,94].Genes implicated in previous autism studies - GWAS and
RNA expression in brain
Of the genes predicted to be alternatively spliced in ASD
versus TD boys in this study, some have been implicated
in previous genetic studies of ASD including Gelsolin
(GSN), LRPPRC (leucine-rich PPR-motif containing),
BIN1 (bridging integrator 1), MED12 (mediator complex
subunit 12), NPAS2 (neuronal PAS domain protein 2),
SYNE1 (spectrin repeat containing, nuclear envelope 1),
and TBL1XR1 (transducin (beta)-like X-linked receptor 1)
[73,89,95-97]. Thus, there is overlap of genes implicated in
Figure 4 Individual-subject level analysis. Hierarchical clustering of ASD subjects and significant pathways (P <0.05). Each ASD subject in each
of the significant pathways was scored as either TD-like, if its PCA position on the PCA plot for the genes with DAS/DEU in the particular pathway
was within 2 SD of the TD centroid (within the TD ellipsoid); or as non-TD-like, if its PCA position on the first three PCA components space was
outside 2 SD of the TD centroid (outside of the TD ellipsoid). An example of the scoring scheme - in the upper right-hand corner - is presented
for the mTOR signaling pathway.
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study of DAS in ASD.
Gelsolin has been implicated in previous genetic studies
of ASD [95], has been reported to be differentially spliced
in ASD compared to TD brain [5], and is predicted to be
alternatively spliced in the ALL ASD versus TD analysis
and the ASD_NTCV versus TD analysis in this study.
Gelsolin protein binds the ‘plus’ ends of actin monomers
and filaments to prevent monomer exchange, and modu-
lates assembly and disassembly of actin filaments. Muta-
tions of this gene cause familial amyloidosis Finnish type
(FAF) [98]. Multiple transcript variants encoding several
different isoforms have been found. Gelsolin levels in-
crease in brain during development, and are higher in
children with Down’s syndrome [99]. In brain gelsolin has
many roles including modulating NMDA receptors, alter-
ing dendritic spines, being highly expressed by oligoden-
drocytes, and modulating amyloidosis [100-102].
The LPPRC gene has also been implicated in previous
ASD genetic studies [73,95]. In the nucleus it binds
HNRPA1-associated poly(A) mRNAs and is part of
nmRNP complexes at late stages of mRNA maturation
which are associated with nuclear mRNA export. In
mitochondria the protein binds to poly(A) mRNA and
stabilizes mitochondrially encoded cytochrome c oxidase(COX) subunits. It cooperates with PPARGC1A to
regulate certain mitochondrially encoded genes and
gluconeogenic genes and may regulate docking of
PPARGC1A to transcription factors and regulates tran-
scription of the multidrug-related genes MDR1 and
MVP. The LPPRC proteinis reduced over two-fold in
ASD compared to control brain [73]. The LPPRC pro-
tein directly binds Neurofibromin 1, mutations of which
can be associated with ASD [103].
MED12 (see above) has also been implicated as a
genetic susceptibility ASD gene [95]. A novel X-linked
disorder with developmental delay and autistic features
with duplication of Xq12-q13.3 involves the MED12
gene [104]. MED12 is linked to the sonic hedgehog
pathway and mutations in the gene are associated with
mental retardation and autism like features [86]. Med12-
dependent recruitment of the Mediator complex with
Sox10 promotes terminal differentiation of myelinating
glia [105]. MED12 plays a key role in forming the hind-
brain during development [84].
TBL1XR1 (transducin (beta)-like 1X-linked receptor 1 -
trascription regulator, beta-catenin binding) has also
been implicated in ASD. It localizes to the histone
deacetylase complex and interacts with HDAC3 and
RNA polymerase II, playing a key role in regulating
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genes that have recurrent mutations that are associated
with ASD [106]. This gene also regulates the beta catenin
Wnt signaling pathway which has also been implicated in
ASD [97,107].
Of the ASD genes found to demonstrate DAS in blood
in this study, several of these have been reported to also
be differentially alternatively spliced in ASD brain. These
include: GSN; CLTB (clathrin, light chain); OS9 (osteo-
sarcoma amplified 9, endoplasmic reticulum lectin);
BIN1; CHPT1 (choline phosphotransferase 1); LSM14A
(SCD6 homolog A); MINK1 (misshapen-like kinase 1);
and SYNE1 [5]. Though the function of these genes may
be different in blood and brain [108], and even though
the exons involved are different as expected since alter-
native splicing is highly tissue-specific, DAS of the same
genes in blood and brain represents an independent line
of evidence for these genes being affected by DAS/DEU
in different cohorts and tissues in ASD.
Pathways previously implicated in ASD: subject-level
pathways affected by DAS in ASD
The pathway analysis summarized in Figure 4 was based
on the 21 pathways that were significantly different be-
tween ALL ASD and TD and which were derived from
477 exons predicted to participate in differential alterna-
tive splicing as well as have a significant difference of
exon expression between ASD and TD. The unique fea-
ture of this analysis was that each pathway was scored as
TD-like or non-TD like for each individual. The data
show that no pathway is associated with all ASD chil-
dren, and only five of 30 ASD children had alterations in
all of the pathways, whereas the remainder had alter-
ations in different subsets of pathways. The finding of
alterations in the Natural Killer Cell and NGF pathways
in the majority of ASD children confirms our and other
previous studies [59-61]. Alterations in genes in
monocyte-related pathways in most ASD children could
relate to reported differential monocyte responses to TLR
ligands in children with ASD [62], to microglia (brain
macrophages) activation in ASD brain [22,109] and micro-
glial genes being over-expressed in ASD brain [5].
Our pathway analyses per individual showed that 60%
of the ASD children in this study had predicted DAS ab-
normalities of mTOR pathways (Figure 4). This is not-
able since mutations of single genes often associated
with ASD clinical features also have aberrant mTOR sig-
naling including Fragile X, tuberous sclerosis, PTEN,
and neurofibromatosis [38,40]. Thus these data point to
possible abnormalities of mTOR pathways in a subgroup
of ‘idiopathic’ ASD which may have clinical relevance
since mTOR inhibitors like rapamycin can modulate
these pathways [110]. Though there are 21 pathways
shared between all of the ASD subjects, and thoughsome subjects share some common pathways, only five
subjects share the same pathways [3]. Thus, a variety of
different combinations of pathways appear to be associ-
ated with idiopathic ASD. This would be consistent with
the many known genetic causes of ASD which are also
associated with many different pathways. However, it
also shows some convergence on similar biological
processes at least for subgroups of ASD subjects as
discussed above [111].
Our novel pathway analysis supports previously pub-
lished data on alterations in pathways in ASD, such as
oxidative stress [61], mTOR [38], Natural Killer cells
[59,60], NGF, and monocyte pathways [112], as well as
activation of microglia (macrophages in the periphery)
[22,109]. However, this is the first study to suggest DAS/
DEU occurs in these pathways and thus confirmation is
needed in a future independent cohort. We performed
this sub-analysis to address the heterogeneity in ASD at
the level of each individual ASD subject. Though every
gene/pathway may not be reproduced, we propose this
as a plausible approach to investigate ASD heterogeneity
and identify ASD subgroups at the transcriptome level.
Differential alternative splicing in ASD with large TCV
There was one gene with DAS in ASD_LTCV when com-
pared to TD: membralin (C19orf6). Membralin is a highly
conserved transmembrane protein, which does not share
significant sequence homology with other human genes,
only membralins of other species. It is expressed in the
central nervous system [113] and is associated with ovar-
ian carcinoma [114]. Membralin interacts with UBC,
TMEM173, and ARSE proteins (www.GeneCards.org;
www.string-db.org). UBC, involved in protein degradation
and ubiquitinization, was a convergence node of direct in-
teractions with genes with DAS in All ASD versus TD and
the LTCV versus NTCVASD comparisons.
Though little is known about membralin function,
some of its interacting partners belong to proteins impli-
cated in ASD. A rare CNV in the AGMO (TMEM195)
gene has been identified with autism in AGRE and
NIMH cohorts [95,115]. In addition, a number of
ubiquitin-related genes have also been implicated in
ASD, and membralin interacts with the ubiquitin C
(UBC) protein [95].
Effect of total brain volume
One surprising result of the study was that though over
100 genes were predicted to demonstrate DAS for the
ASD_NTCV versus TD comparison, only one gene was
predicted to show DAS for the ASD_LTCV versus TD
comparison (membralin). This could be interpreted to
mean that DAS/DEU is associated more with the patho-
physiology of ASD with normal brain volumes rather
than ASD with large brain volumes. If this is the case,
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is consistent with a different pathophysiology of the
ASD_LTCV and ASD_NTCV subgroups. There were 27
genes that demonstrated DAS in the ASD_NTCV versus
ASD_LTCV comparison, which associated with many
pathways including IL12 signaling in macrophages, In-
ositol Pyrophosphates Biosynthesis, synaptic long-term
potentiation, PKA signaling, Dopamine-DARPP32 Feed-
back in cAMP Signaling, and others. Given that only
one gene differed in the ASD_LTCV to TD comparison,
these differences are likely driven by the ASD_NTCV
group. The data would suggest that future genetic, im-
aging, biomarker, and behavioral studies should consider
head size for defining clinical ASD subgroups.
Limitations
Cause and effect cannot be determined from this study.
Since blood samples were used, it is not known to what
extent the observed changes reflect changes in the brain.
It is likely that many of these changes reflect differences
in the peripheral immune system of ASD and are associ-
ated with the immune and autoimmune dysregulation
observed in some ASD subjects [112].
The sample size is small and though multiple compari-
son adjustments were made, the problem of false posi-
tives can only be addressed by replication in future
studies. CNVs, SNPs, and other processes could affect
the exon usage measured in this study which would not
represent differences of alternative splicing. Therefore,
alternative splicing predicted using exon arrays in this
study will require confirmation using other approaches
that directly measure expression of alternatively spliced
variants of single genes. The current study provides one
source for determining which genes might be evaluated
in future studies.
Conclusions
The data in this study suggests that DAS occurs in blood
of 2-4-year-old boys with ASD compared to TD con-
trols. Different ASD subgroups based on TCV exhibited
specific DAS. These findings are preliminary and need
to be replicated in independent cohorts.
Additional files
Additional file 1: Figure S1. Principle components analysis (PCA) on a
whole-genome level of all samples included in our analyses. Color-coding
based on Group: TD - blue, ASD_NTCV - orange, ASD_LTCV - gray.
Figure S2. IPA top-scoring networks of the 53 genes with DAS/DEU
(ALL ASD vs. TD): Free Radical Scavenging , Cell Death and Survival, Small
Molecule Biochemistry. Red - predicted exon with DAS/DEU is more
often retained in ASD than in TD; green - predicted exon with DAS/DEU
is more often excluded in ASD than in TD. Solid lines represent direct
interactions. Dashed lines - indirect interactions. Note: PI3K node, which
displays DAS. Colors represent genes predicted to display DAS/DEU
between ALL ASD and TD. Figure S3. IPA second top-scoring networksof the 27 genes with DAS/DEU in ASD_LTCV vs. ASD_NTCV: Cellular
Assembly and Organization, Cellular Function and Maintenance, RNA
Post-Transcriptional Modification. Note: UBC convergence hub of direct
interactions. Colors represent genes predicted to display DAS/DEU
between ASD_LTCV and ASD_NTCV and TD. Red - predicted exon with
DAS/DEU is more often retained in ASD_LTCV than in ASD_NTCV; green -
predicted exon with DAS/DEU is more often excluded in ASD_LTCV than
in ASD_NTCV. Solid lines represent direct interactions. Dashed lines -
indirect interactions.
Additional file 2: Table S1. Genes (n=53) with predicted DAS/DEU in
ALL ASD vs. TD groups (FDR P <0.05). Table S2. Genes (n=169) with
predicted DAS/DEU in ASD_NTCV vs. TD groups (FDR P <0.05). Table S3.
Genes (n=27) with predicted DAS/DEU in ASD_LTCV vs. ASD_NTCV
groups (FDR P <0.05). Table S4. Genes (n=477) with predicted DAS/DEU
in sub-analysis of ALL ASD vs. TD Groups for individual subject-level
pathway analysis. Table S5. Functional analysis using IPA of the 477 DAS
genes in the sub-analysis of ALL ASD compared to TD (see Table S4)
revealed that 21 canonical pathways were over-represented (P <0.05).
These 21 pathways and the genes with DAS in each pathway are listed
below. These 21 pathways were used for the analysis shown in Figure 4.
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